Apexigen America, Inc.
11
0
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
27.3%
3 terminated/withdrawn out of 11 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
100%
6 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer
Role: collaborator
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
Role: collaborator
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Role: collaborator
APX005M and Doxorubicin in Advanced Sarcoma
Role: collaborator
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Role: collaborator
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Role: lead
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Role: lead
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Role: lead
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Role: lead
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Role: collaborator
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
Role: collaborator
All 11 trials loaded